



RNA and DNA viruses

Petr Hubáček



Dept. of Medical Microbiology and Paediatric Haematology and Oncology
2nd Medical Faculty of Charles University and Motol University Hospital




DNA viruses




RNA viruses



Clinical consequences



Balance in the (immunocompromised) patient



Methods of the viral detection

Detection methods in virology

- Microscopic Direct detection
- Cultivation
- Detection of the antigen
- Detection of the nucleic acid
- Detection of the antibodies
- (Signs of disease)

Indirect detection

Methods of the viral detection - INDIRECT

Signs of the disease


Clinical signs of disease leading to suspicion of viral infection (poliomyelitis) were described first 3 700 BC in Egypt.

Typical signs are e.g. in:

- varicella
- zoster
- fully developed IM
- papillomaviral infection (wart)
- also in HHV-8 and other viral infections

Group of disease related to RNA viral infections

- Respiratory tract infections** – influenza, PIV, RSV, hantaviruses...
- CNS infections** – enteroviruses, parechoviruses, flaviviruses (WNV), TBE,...
- Liver infections** – picornaviruses (HAV), flaviviruses (HCV, Yellow fever...)
- Kidney infections** – hantaviruses,...
- Immune related infections** – HIV
- GIT infections** – astroviruses, calciviruses, rotaviruses
- Haemorrhagic fevers** – Lassa virus, Ebola virus, Marburg virus...
- Exanthematic diseases** – Mumps virus, Rubella, Dengue...



How often do we detect viruses at ICU?

Detected	Pneumonia (n=185)	Control group (n=25)
HSV	51 (27.5%)	7 (28%)
CMV	31 (16.8%)	3 (12%)
PIV-1	3 (1.6%)	1 (4%)

Bousbia et al. PLoS 2012

BMC Pulmonary Medicine 2009, 9:22 <http://www.biomedcentral.com/1471-2468/9/22>

A. Detected primary responsible (leading) infectious agents in 63 patients with ambulatory-acquired pneumonia/pneumonitis and autoimmune disease:

- none detected: 38 (60.3%)
- multiple agents: 3 (4.8%)
- H. influenzae: 3 (4.8%)
- K. pneumoniae: 2 (3.2%)
- Legionella/Chlamydia: 2 (3.2%)
- Mycobacteria: 2 (3.2%)
- HSV-1: 2 (3.2%)
- S. aureus: 1 (1.6%)
- S. pneumoniae: 1 (1.6%)
- Strep. spp.: 1 (1.6%)
- Enterococci: 1 (1.6%)
- Ps. aeruginosa: 1 (1.6%)
- Bacteroides: 1 (1.6%)
- Pr. Jirovecii: 1 (1.6%)
- Aspergillus: 1 (1.6%)
- Candida: 1 (1.6%)
- RSV: 1 (1.6%)
- MTX-pneumonitis: 1 (1.6%)

B. Immunosuppression scores were significantly more severe in the 6 patients with HSV-1 detection in BAL than in those subjects without clinical or laboratory evidence for HSV-1 (as assessed for 56/63 patients with reliable information on immunosuppressive regimens available; ¹⁰⁰ p < 0.01, Mann-Whitney two-sided test).

How often do we detect viruses at ICU? Hematooncological patients

- RSV**
 - in 0.3% - 2.2% of paediatric pts with AML and 1%-12% adult HSCT pts
 - UTRI to LRTI progression in 20-68% pts.
 - RSV related mortality 17-70%
- PIV**
 - PIV causes URTI during year from laryngotracheitis, bronchiolitis to pneumonia in 15% of children from autumn to spring
 - In patients after HSCT in 2% - 7% symptomatically, when asymptomatic patients are included up to 18%
 - Long lasting expression can lead to nosocomial epidemic.
 - PIV-3 is after HSCT most frequently (up to 90% of cases) later PIV-1 a - 2
 - URTI decrease of ventilation up to 40%, infection progress to LRTI in 13-37% with fatal end 10-30%.
- hMPV**
 - Related to RSV causing 5%-20% of URTI and tracheobronchitis in children and adults during winter
 - At HSCT patients described in 5%-9% during first 2 years after HSCT.
- Coronavir**
 - In pts. after HSCT detected in 6.7% - 15.4%, asymptomatic shedding in 41%..
 - In symptomatic pts. often coinfections
- HRhV**
 - HRhVs most frequent viral cause of CARI with cumulative incidence up to 22.3% at D+100.
 - Asymptomatic in 13% of HSCT patients, detection with other CARI viruses in 19%
 - LRTI in allogeneic HSCT rare (<10%), might be associated with bad outcome in less than 10%

Hantaviruses




- Bunyaviridae
- ss(-) RNA - 3 segments (small ~ 1.7-2 kb, medium ± 3.7 kb, large ± 6.5 kb)
- enveloped 120-160 nm in diameter
- Incubation period – 2-4 weeks
- The described in 1951, where a hantavirus caused hemorrhagic fever with renal syndrome (HFRS) in North and South Korea.
- Transmitted from rodents, even pet rodents.
- The viruses that caused HFRS in Asia were later grouped as Old World Hantaviruses.
- In 1993 (southwestern USA) was described hantavirus pulmonary syndrome (HPS) - Sin Nombre.
- Hantavirus strains that occur globally – affecting kidneys and lungs mainly.
- Airborne transmission
- Underdiagnosed diseases.

Hantaviruses

- HFRS – viruses - Dobrava, Hantaan, Puumala a Seoul. Mortality is highest in Hantaan virus – 5–15 %; Puumala and Seoul virus about 1%.
- HPS (Sin Nombre) rare 534 case (1993-2009) – mortality rate 36%.

List of Hantaviruses:


Andes virus, Amur virus, Asama virus, Azagry virus
 Bayou virus, Black Creek Canal virus, Bloodland Lake virus, Blue River virus
 Cano Delgado virus, Calabazo virus, Carizal virus
 Cacacemas virus, Choclo virus
 Dobrava-Belgrade virus
 El Moro Canyon virus
 Gou virus, Hantaan River virus
 Huitzilac virus, Irinj virus
 Itala Vista virus, Khabarovsk virus,
 Laguna Negra virus, Limestone Canyon virus
 Migdol virus, Maripa virus, Monongahela virus, Montano virus
 Mouyassue virus, Muleshoe virus, Muju virus, New York virus
 Nova virus, Ocan virus, Oxbow virus, Playa de Oro virus
 Prospect Hill virus, Puumala virus, Rockport virus
 Rio Mamore virus, Rio Segundo virus, Sangassou virus
 Saaremaa virus, Seoul virus, Serang virus, Sin Nombre virus
 Soochong virus, Tanganya virus, Thailand virus, Thotapatayam virus
 Topografov virus, Tula virus, Xuan Son virus



AUUUU.ORG

<http://www.auiuuu.org/responsive/pictures/hantaviruses.jpg>

CSF



ADA



Neurotropic viruses

- Neurotropismus (encefalitis)
 - Coronaviridae -
 - Flaviviridae – e.g. West Nile virus (WNV), Japanese encephalitis virus (JEV), Murray Valley encephalitis virus (MVEV), St. Louis encephalitis virus (SLEV), tick-borne encephalitis virus (TBEV)
 - Lentiviridae - HIV
 - Herpesviridae – HSV-1, 2, CMV, HHV-6, HHV-7, EBV (?)
 - Paramyxoviridae – Morbillivirus, Hedra a Nipah virus
 - Picornaviridae - enteroviry
 - Rhabdoviridae – Lyssa
 - Polyomaviridae – JCV (PML)

Symptoms associated with CNS disease

	Observed	-- Rare	++ Often
Clinical symptoms			
Fever		--	++
Head ache		--	++
Decrease of the mental status	Stabil worsening		Status fluctuation
Focal neurological symptoms		--	++
Seisures	Generalized		Generalized and focal
Lab.-Blood	Leukocytosis --		Leukocytosis ++
Lab.-CSF	Pleocytosis --		Pleocytosis ++
Lab.-EEG	Diffuse decrease of waves		Diffuse decrease of waves and focal abnor.
Lab.-MRI	Often normal		Focal abnormalities

Kennedy J Neurol Neurosurg Psychiatry 2004;75 (Suppl I).

Differential diagnosis of encephalitis

ADEM – acute disseminated encefalomyelitis

CNS vasculitis (including VZV)

Non-virus associated infectious encephalitis

Encephalopathy

- Anoxic/ischaemic
- Metabolic
- Nutritional deficiency
- Toxic
- Systemic infections
- Critical illness
- Malignant hypertension
- Mitochondrial cytopathy (Reye's and MELAS syndromes)
- Hashimoto's encephalopathy
- Paraneoplastic
- Neuroleptic malignant syndrome
- Traumatic brain injury
- Epileptic (non-convulsive status)

- Bacterial
- Mycobacterium tuberculosis
- Mycoplasma pneumoniae
- Listeria monocytogenes
- Borrelia burgdorferi
- Legionnaires
- Brucellosis
- Leptospira
- Legionella
- Trichinella spiralis (Whipple's disease)
- Naissia meningitidis
- Trichinella spiralis
- Trichinella spiralis
- Trichinella spiralis
- All cases of pyogenic meningitis
- Rickettsial
- Rickettsia rickettsii (Body Mountain spotted fever)
- Rickettsia typhi (endemic typhus)
- Rickettsia prowazekii (epidemic typhus)
- Coxiella burnetii (Q fever)
- Ehrlichiosis (Ehrlichia chaffeensis – human monocytic ehrlichiosis)
- Fungal
- Cryptosporidium
- Aspergillus
- Candida
- Coccidioides
- Histoplasma
- North American blastomycosis
- Parasitic
- Naissia meningitidis (sleeping sickness)
- Cerebral malaria
- Toxoplasma gondii
- Echinococcus granulosus
- Schistosoma

Kennedy J Neurol Neurosurg Psychiatry 2004;75 (Suppl I).

Most frequently detected viruses according the risk factors


Risk factor	Possible aetiological agent
Unvaccinated status	Polio, measles, mumps, rubella viruses
Animal contact	Rabies virus, cat scratch disease, Hendra virus, Q fever
Bird contact	WNV, Japanese encephalitis, <i>Cryptococcus neoformans</i>
Insect contact	Malaria, WNV, tick-borne encephalitis virus, typhus, Lyme disease, trypanosomiasis
Ingested meat/unpasteurised milk	Toxoplasmosis, listeria, Q fever
Sexual contact	HIV, syphilis
Swimming	Enteroviruses, <i>Naegleria fowleri</i>
Camping/hunting	Malaria, tick-borne encephalitis virus, typhus



Thompson et al. Arch Dis Child 2012;97:150-161.

Most frequently detected viruses according to the clinical symptoms

Clinical presentation	Possible aetiological agent
Cranial nerve abnormalities	HSV, EBV, listeria, tuberculous meningitis, syphilis, Lyme disease, <i>Cryptococcus neoformans</i>
Cerebellar ataxia	VZV, EBV, mumps virus, trypanosomiasis
Dementia	HIV, measles virus, syphilis, human transmissible spongiform encephalopathies
Polioymyelitis-like flaccid paralysis	JEV, poliovirus, enteroviruses, WNV, tick-borne encephalitis virus
Parkinsonism	JEV, WNV, Ngah virus
Retinitis	CMV, WNV, cat scratch disease, syphilis
Rash	VZV, HHV-6, rubella virus, typhus, syphilis, Lyme disease, WNV, HIV, enteroviruses, <i>Mycoplasma pneumoniae</i>
Respiratory tract findings	Flu virus, adenovirus, <i>M pneumoniae</i> , <i>Mycobacterium tuberculosis</i> , Q fever
Parotitis	Mumps virus
Lymphadenopathy	HIV, EBV, CMV, measles virus, rubella virus, WNV, syphilis, cat scratch disease, tuberculous meningitis, toxoplasmosis, trypanosomiasis
Hepatitis	Q fever



Parotitis virus

Thompson et al. Arch Dis Child 2012;97:150-161.

Picornaviridae - Enteroviruses


- ss(+) RNA, genome 7.2-8.5 kb
- Most frequent cause of encephalitis/meningoencephalitis (90%)
- Different serotypes (dividing to) – Polioviruses
 - Coxsackieviruses (e.g. Myocarditis, Hand Foot Mouth disease...)
 - Echoviruses
 - Other... (e.g. Enterovirus 71, human rhinoviruses, HAV)
- Symptoms – very different – conjunctivitis, hepangine, start of T1DM, exanthema, neonatal sepsis, pleurodynia...
- Encephalitis/myeloencephalitis
 - Prodromal symptoms - fever, chills, headache, photophobia and nuchal rigidity; rash and upper respiratory symptoms
 - fever and meningeal signs subside within 2-7 days
 - Most frequent - Coxsackievirus B, echoviruses
 - EV-71 particularly aggressive CNS infection

Hand Food & Mouth Disease

Hand, foot, and mouth disease, or HFMD, is a contagious illness that is caused by different viruses. Infants and children younger than 5 years old are more likely to get this disease. However, older children and adults can also get it. In the United States it is more common for people to get HFMD from spring to fall.

Symptoms

- It may last 7-10 days.
- Hand-foot-and-mouth disease may occur in all of the following ways and sometimes in all of them. They include:
 - Fever
 - Sore throat
 - Painful blisters (small sores) in the mouth
 - Small, red, itchy rashes on the hands, feet and sides of the torso
 - A sore throat, without blisters but sometimes with blisters on the tongue, sides and sometimes the larynx
 - Blister-like rashes and rashes
 - Loss of appetite





Picornaviridae - Enteroviruses

- Salk vaccine - first tested in 1952 – injected inactivated (dead) poliovirus
- Sabine vaccine - oral attenuated poliovirus – trials began in 1957, licensed in 1962

MUSCLES COMMONLY WEAKENED BY POLIO

Jonas Salk
Creator of the original polio vaccine.

GLOBAL CITIZEN

Picornaviridae - Enteroviruses

- Vaccines eradicated polio from most countries in the world, and reduced the worldwide incidence from an estimated 350,000 cases in 1988 to just 223 cases in 2012.
- In November 2013, the WHO announced a polio outbreak in Syria.

Flaviviridae

- avr. 40-60 nm
- ss (+)RNA approx. 11 kb
- virions 3 structural proteins – env. gp, core and membrane protein
- replication in cytoplasm, lipid envelope is got during budding from cytoplasmic vesicles
- disease has often „two“ waves of clinical symptoms

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828282/figure/Fig1/Fig1_10.jpg

Tick Borne Encephalitis – TBE
geographical distribution

- not west from Austria
- discovered in Austria in 1931
- in Czech Republic (CS) was first isolated independently in two places (dr. Gallia, Rampas, Křejč) in 1949 – 1st TBE isolation in Europe.

■ Eur-TBEV
■ Eur-Sib-TBEV
■ Sib-TBEV

TBE Vector

in 1937 rusion scientist L. A. Zilber proved transmission with tick (in russian spring-summer encefalitis)

Western subtypes **Both types** **Eastern subtypes**

Tick Borne Encephalitis – TBE symptoms and diagnosis

Diagnosis:
IgM-antivirals of serum (EIA)
Total antivirals of serum (HI)

- Vaccination - inactivated virus

Tick Borne Encephalitis – TBE symptoms

- 2/3 of infections asymptomatic
- Incubation period - 8 days (range 4–28 days)
- I: nonspecific febrile illness, headache, myalgia and fatigue. - Up to 2/3 of patients may recover without any further illness.
- II: CNS - aseptic meningitis, encephalitis, or myelitis. Disease severity increases with age.
- The European subtype - milder disease, a case-fatality ratio of <2%, and neurologic sequelae in up to 30% of patients.
- The Far Eastern subtype – often more severe disease course, a case-fatality ratio of 20%–40% and higher rates of severe neurologic sequelae.
- The Siberian subtype - more frequently chronic or progressive disease and has a case-fatality ratio of 2%–3%.

Vaccination - inactivated virus

Flaviviridae Zika virus

- Described in apes (Makak rhesus) in Uganda during monitoring of the yellow fever in 1947.
- In humans described for the first time in Uganda and Tanzania in 1952 v Ugandé. Subsequently recognised in Africa, Asia, and Pacific (2007-2013) and America (2015 – Brazilia and Columbia).

How Zika virus spread from Africa

Source: Lancaster University

Flaviviridae Zika virus

- Transmitted by mosquitos genus Aedes (especially A. aegypti) by blood.
- Transmission is described also by blood directly, perinatal transmission, amniotic fluid, CSF and sperm.

(However, there are doubts about real presence of the virus in the sperm, or blood contamination).

Flaviviridae Zika virus

- Incubation period 3-12 days
- Zika fever is presented with fever, conjunctivitis, rash, pain of muscles, joints, and head, malaise lasting for about 2-7 days.



Flaviviridae

Zika virus

Microcephaly was described in infection during pregnancy during outbreak in Brasil in 2015.

Risk of microcephaly in retrospective study from French polynesia 95 (34–191) 10 000 women + 0,95% In Brasil 29%. (NEJM, Lancet 2016)



Described as causal pathogen in myelitis and Guillain–Barré syndrome. (NEJM 2016)


Rhabdoviridae

Lyssavirus

- ss (-) RNA; genome 11 kb
- enveloped
- 75 nm wide and 180 nm long
- cellular receptor: acetylcholine receptor
- Transmission: mainly from infected animals by saliva
- Clathrin mediated endocytosis
- Cytoplasmatic proliferation – **Negri bodies**

Purkinje cell - Negri body



Rhabdoviridae

Lyssavirus - Rabies

- Incubation: av. 3-12 weeks (1 week to 15 months)
- Retrograde transport from periphery to CNS
- Prodromal phase (1-2 days), symptoms (3-4 days) after 5 days encephalitis and paralysis
- Encephalitis and/or myelitis (in fully developed 100%)





How it spreads

ANIMAL BITE: The farther away from brain, the longer virus takes to spread

VIRUS: Spreads through central nervous system

Common carriers of rabies

Infected animals: Show no fear for humans; act very agitated


Dog: Another common rabies source

Symptoms in humans

- Fever, depression
- Agitation
- Painful spasms followed by excessive saliva
- Death within a week without vaccine

Treatment: Hospitalization, immune globulin injections, anti-rabies vaccine

Foaming at mouth after drinking: Produced by spasms in throat




<http://peterandmorrisonrabies.weebly.com/uploads/5/5/7/53574157/807037792.png>

Rhabdoviridae


Lyssavirus - Rabies

Risk of the lyssavirus exposition in the world (WHO 2013)



- Prevention – animal vaccination
- **Pre-exposition vaccination** (persons working with virus, animals or close to them) – laboratory technicians, forest workers, rangers, hunters...
- **Post-exposition vaccination**

Zdroj: www.vakciny.net



Most frequent viral pathogens


- Astroviruses
- Norovirus
- Rotavirus
- Adenovirus
- „All“ are agents of watery diarrhea together with vomiting
- Incubation period 1-4 (9) days
- Lasting 2-8 days
- Highly infectious (norovirus 1-10 particles)
- And others
 - Enteroviruses
 - Influenza...

Astrovirus VA1/HMO-C: An Increasingly Recognized Neurotropic Pathogen in Immunocompromised Patients

Julianne R. Brown,^{1,2} Sofia Morfopoulou,³ Jonathan Hubb,⁴ Warren A. Emmett,² Winnie Ip,⁵ Divya Shah,² Tony Brooks,⁶ Simon M. L. Paine,^{7,8} Glenn Anderson,² Alex Vinasami,² C. Y. William Tong,⁴ Duncan A. Clark,⁴ Vincent Plagnol,² Thomas S. Jacques,^{2,9} Waseem Qasim,⁵ Mike Hubank,⁵ and Judith Breuer^{1,8}

¹Virology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, ²NHRI Biomedical Research Centre, Great Ormond Street Hospital for Children NHS Foundation Trust and University College London, ³UCL Genetics Institute, University College London, ⁴Virology Department, Barts Health NHS Trust, ⁵Molecular and Cellular Immunology, ⁶Molecular Haematology and Cancer Biology Unit, Institute of Child Health, University College London, ⁷Department of Histopathology, Great Ormond Street Hospital for Children NHS Foundation Trust, ⁸Department of Infection and Immunity, and ⁹Birth Defects Research Centre, Institute of Child Health, University College London, United Kingdom

Neurotropic Pathogen HAstV VA1/HMO-C • CID 2015;60 (15 March) • 881



doi:10.1093/cid/civ020
www.ncbi.nlm.nih.gov/pmc/articles/PMC4244194/

DNA viruses



Indicative disease for HIV re-classification to AIDS stage (WHO criteria):

1. pneumocystis pneumonia
2. toxoplasma encephalitis
3. esophageal, tracheal, bronchial or lung candidiasis
4. **Chronic anal herpes simplex or herpetic bronchitis, pneumonia or esophagitis**
5. **CMV retinitis**
6. **generalized CMV infection (excluding liver and spleen)**
7. **progressive multifocal leukoencephalopathy**
8. repeating salmonella bacteremia
9. repeating pneumonia within 1 year
10. chronic intestinal cryptosporidiosis
11. chronic intestinal isosporosis
12. extrapulmonary cryptococcus infection
13. Disseminated or extrapulmonary histoplasmosis
14. disseminated coccidioidomycosis
15. tuberculosis
16. disseminated or extrapulmonary atypical mycobacteriosis
17. **Kaposi's sarcoma**
18. **malignant lymphoma (Burkitt's lymphoma, immunoblastic and primary cerebellar lymphoma)**
19. Invasi carcinoma of cervix
20. HIV encephalopathy
21. wasting syndrom




Polyomaviruses




- small ds DNA viruses with circular NA
- Capsid diameter 42-45 nm, genome: 5 kbp
- Transmission by fecal-oral route
- **JC virus** – progressive multifocal leukoencephalopathy PML
- **BK virus** – hemorrhagic cystitis, nephropathy (graft rejection in kidney transplant)
- **WUV and KIV** – respiratory infections
- **MCV** – Merkel cell carcinoma virus (rare skin carcinoma)
- **HPyV 7-12** (Human Polyomavirus) – mainly skin viruses
- Potentially treatable with **cidofovir**



Patient 4 BKV – haemorrhagic cystitis



Age at HSCT: 18 let, Fanconi anemia, MUD 9/10, BM, aGvHD grade I.



Papillomavires

- ds DNA virus
- DNA length approx. 8 kb
- > 100 serotypes
- causing – warts
 - Condylomata accuminata
 - Epithelial carcinoma
 - cervix
 - larynx
 - penis ...
- genital warts around 30 types
- most of the people gets infected in first 2-3 years of sexual activity (2/3 within 1st 3 months)

Common Wart: Common on hand and knuckles but may appear anywhere.

Plantar Wart: On soles heel or toes of feet.

Flat Wart: Usually on leg hand face.

Filiform Wart: Usually on face near eyelids lips.

Mosaic Wart: Group of tightly clustered warts.

Periungual Wart: Wart around finger nail toe nail.

Oral Wart: Within oral cavity.

Genital Wart: Located near or in genital areas.

Papillomaviruses

HPV-LR low risk
6, 11, 40, 42, 43, 44, 54, 61, 70, 72 a 82 (condylomata accuminata, ca.)

- 2-8 months after infection is necessary for lesion development on 50% of infected women
- non-oncogenic
- delected usually around 25 yrs.


HPV-HR high risk
High risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56 a 86

- unifocal lesion (CIN 1–3 a ca.)
- transmission by sex, contact
- highly protective specific immunity
- in 35 years (CIN 3) and 45 yrs. (ca.)
- CIN 3 after 18M-5 yrs. after infection
- 80–90 % of women eliminate virus spontaneously within 8–16 months
- from 10–20 % of women with lasting infection:
 - 20 % develops CIN 3 within 5 yrs.
 - 5 % develops ca. until 15–20 yrs. (in women with regular preventive testing only 1 % really develops ca.)

Papillomaviruses – genome

Gene	Function
L1	Major capsid protein.
L2	Minor capsid protein.
E1	Transcription factor, helicase activity. Mediates episomal DNA replication.
E2	Transcription factor. Regulates viral copy number.
E4	Facilitates virion release.
E5	Stimulates cell proliferation and prevents differentiation. Downregulates surface MHC class I expression.
E6	Deregulates cell cycle control through p53 inactivation/degradation. Induces malignant transformation together with E7.
E7	Keeps cells active in the cell cycle through Rb inactivation. Induces malignant transformation alone and together with E6.

Papilomaviruses – oncogenic potential



HPV 16 a 18

Causes up to:

- 70% of cervical carcinoma
- 80% rectal ca.
- 60% ca. of vagina
- 40% ca. of vulva
- 90% of genital warts



- HPV is most frequently transmitted STD in MSW adults

- (> 80% of american women got at least 1 HPV typ at the age of 50)
- 529,000 of new cervical ca. cases and 275,000 deaths/year



• VACCINATION!!!

HPV vaccines: Gardasil(Silgard) Cervarix




Adenoviruses

- non enveloped ds DNA viruses
ikosaedral structure 70-75 nm
genome: 35 kbp
according to similarity – 7 subgenes A-G
according to antigenic specificity – more than 60 serotypes
- Acute faryngitis, Faryngoconjunctivitis, Acute respiratory tract infection, Pneumonia, Acute hemorrhagic cystitis, Keratokonjunktivitis, Pertussis-like sy., Hepatitis, Gastroenteritis, Meningoencefalitis, Myokarditis
- Persistence in BMT, patients with immunodeficiencies or immunosuppression – in colon, and urinary tract




Serotypes




Group	Serotypes	Localisation of the infection
A	12, 18, 31	Respiratory, urinary, GIT infections and CNS infections; in HSCT patients rare.
B	3, 7, 11, 14, 16, 21, 34, 35, 50	Respiratory, eye, urinary, GIT and CNS infections.
C	1, 2, 5, 6	Respiratory, urinary and GIT infections – hepatitis too.
D	8-10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39, 42-49, 51	Eye, GIT and CNS infections; in HSCT patients rare.
E	4	Eye and respiratory tract infections; in HSCT patients rare.
F	41	GIT infections; in patients after HSCT rare.
G	52	GIT infections.

Rozdělení adenovirových infekcí do skupin (upraveno dle Fields Virology 5th edition, Kapitola 63).





Patient 6



Dívka Věk při HSCT: 1 rok Dg.: ALL v CR2 Štěp: CB (5/6)
Příprava: busulfan, cyklofosamid, melfalan a ATG Příhojení D+25.
GvHD grade II (GIT1, kůže 3) léčená kortikoidy.
Kompletní chiméra ode D+14.

Patient 7





Parvovirus B19

- small non-enveloped ss DNA +/-
- capsids in diameter 20-26 nm, genome: 5 kbp
- proliferation in erythroid progenitors – transient stop of erythrocyte production and so it leads in certain clinical situations (e.g. Hereditary erythrocytosis disorders) to anaemia.
- E.g. aplastic crises, Bone marrow aplasia, teratogenicity-hydrops foetalis.
- **Fifth exanthematic disease** (see lecture)

Parvovirus B19

Work-up of nonimmune hydrops foetalis*

Swollen liver, Severe abdominal swelling

Source: BPPV. Nonimmune hydrops foetalis. Am J Obstet Gynecol. 2015. *Requires negative antibody screen and normal fetal chest to rule out alloimmunization. *CMV/HSV testing if fetal anomalies suggestive of infection. †Other seronegative or FBS. ‡Available in some laboratories. Abbreviations: CMA, chorionic villus sampling; CMV, cytomegalovirus; GAD65, glucose-6-phosphate dehydrogenase deficiency; PCR, polymerase chain reaction; FBS, fetal blood sampling; MCA, middle cerebral artery.

Poxvirus

- Complex structure (symetria)
- Enveloped but resistant to inactivation
- linear ds DNA
- Genome 130–375 kb coding approx. 250 genes (>100 polypeptides-often immunogenic)
- Replication in cytoplasm
- Highly species specific
- Used for genome vector constructions
- Human pathology is associated with 4 genera:
 - Orthopoxvirus
 - Parapoxvirus
 - Yatapoxvirus
 - Molluscipoxvirus

Orthopoxvirus

- Variola virus
 - Variola major (mortality 20%), variola minor (mortality 1-2%)
 - Eradicated (last diagnosed in 1977)
 - All eruptions in same status of development
 - Primary replication in air-ways
- Vaccinia virus (used for vaccination and eradication of variola)
- Cow pox virus (first vaccination against variola – Edward Jenner – 1796)

Parapoxvirus

- Zoonosis
- Human infections causes
 - Bovine papular stomatitis virus
 - Orf virus
 - Pseudocowpox virus
- Afters eruptions on mucous and/or skin

Clinically called "farmyard pox"

Orf (Ecthyma contagiosum)

- **C/P:**
 - Typically presents as a papule/nodule on the dorsal index finger.
 - **Progression through several stages:**
 - maculopapular
 - targetoid
 - weeping nodule
 - regenerative dry stage with black dots
 - papillomatosis
 - regression with a dry crust
 - **Other Findings:** Ascending lymphangitis, lymphadenopathy, malaise, and fever may occur.
 - Bacterial superinfection may occur.
 - Erythema multiforme occasionally occurs 10 to 14 ds. later

Yatapoxvirus

- Yaba monkey pox virus
 - Oncogenic virus – histiocytomas (tumour from macrophages) in humans and monkeys (e.g. *Macaca fascicularis*)
 - Presence by the river Niger



https://upload.wikimedia.org/wikipedia/commons/9/9f/Macaca_fascicularis.jpg

https://en.wikipedia.org/wiki/Monkeypox_virus#Media/File:Monkeypox.tif

Molluscipoxvirus

- Molluscum contagiosum
 - Viral infection of skin, rarely mucous membranes
 - Charakteristic skin lesions
 - Infection of human, primate and kangaroos
- 4 types
- Often STD (MCV 1,2)
- Incubation period – up to months




<http://www.dermapics.com/molluscum%20contagiosum.html>

<http://www.molluscum.com/molluscum-contagiosum-pictures/>



Therapeutical possibilities of virostatics and specific antibodies


More or less specific for certain viral groups:



Virostatic drugs impact

Virostatics

usually cellular nucleotides analogues blocking (more or less specifically) viral polymerase (acyklovir, ganciklovir, cidofovir...), or polymerase directly blocking drugs without similarity to nucleosides (e.g. foscarnet) or viral protein blocking drugs (neuraminidase inhibitors..)



Antibodies with virostatic effect

Neutralising antibodies against certain proteins important in pathogenesis of viral disease (F protein in RSV) or aimed against target cells (anti-CD20 in EBV).

Anti CD-20



Dosing of most frequently used virostatic drugs

- acyclovir (HSV, VZV)
 - **Prophylactical dosing** – 500 mg/m²/dose in infusion for 60 minut twice daily with maximum 750 mg/dose
 - **Therapeutical dosing** – for 7–10 days 250 mg/m²/dose in infusion for 60 minutes á 8 hours with maximum of 500 mg/dose (resp. 10–15 mg/kg/dose)
- ganciclovir (CMV, HHV-6, HHV-7)
 - **Therapeutical dosing** – at least 3 weeks 2 weeks 5 mg/kg/dose in infusion for 60 min á 12 hours, 2 týdny; subsequently 5 mg/kg/dose in infusion for 60 min/ day
- foscarnet (CMV, HHV-6, HHV-7, HSV, VZV)
 - **Therapeutical dosing** – for 3 weeks 60 mg/kg/dose in infusion for 60 min (or i.v.) á 12 hours, 1–2 weeks; subsequently 90 mg/kg/dose in infusion for 60 min (or i.v.) á 24 hours
- cidofovir (CMV, HHV-6, HHV-7, HSV, VZV, adenoviruses, BKV, ...)
 - In case of CMV disease 5 mg/kg/dose in infusion (1/1 fysiological solution) 1x week
- oseltamivir (Influenza)
 - **Prophylactical dosing** – 30–60 mg in children younger 12 yrs. according to the weight (>15 kg – 30 mg, 15 to 23 kg – 45 mg, 23 to 40 kg – 60 mg), in patients older 13 yrs. and heavier 40 kg then 75 mg for at least 10 dni.
 - **Therapeutical dosing** – at least 10 days in children and adults; dvojnásobek prophylactical dosing – in adults 75 mg 2x day, in very severe cases 150 mg 2x day.

Adverse effects of the virostatic drugs

- **Acyclovir/valaciclovir**
 - **AE usually reversible**, usually in patients with hepatopathy.
 - rarely haematopoietic and lymphatic system disorders (anaemia, leucopenia, thrombocytopenia), hepatitis, nephrotoxicity.
- **Ganciclovir/valganciclovir**
 - **myelosuppressive effects** (neutropenia (25–40 %), thrombocytopenia (9-20 %))
 - nausea, vomiting and diarrhea, increase of the liver enzymes: confusion and seizures; renal insufficiency (rarely in patients after heart tx.); enormously rare exanthema or eosinophilia
- **Foscarnet**
 - **Nephrotoxicity**- rarely acute renal failure (uremia and polyuria), potentially metabolic acidosis and diabetes insipidus
 - Increase of the liver enzymes, LDH, ALP and amylasis; often nausea, vomiting nad diarrhea, rash (exanthema), tremor, muscle weakness and increase in body temperature, thrombocytopenia, hypokalemia, hypomagnezemia, hypo- or hyperfostataemia, **hypocalcemia** (shortly after infusion or tonic-clonic seizures) – increased risk in CNS disorder or ciprofloxacin administration
 - Headache, tiredness, paresthesia, tremor, ataxia. Neuropathy, hypestazia, confusion, depression, psychosis, aggressive reactions, psychosis, aggressive reactions; changes in ECG, hyper- hypotension, rarely even chamber arhythmias
 - Often Phlebitis (thrombophlebitis) in administration of concentrated solutions (> 12 mg/ml) to peripheral vein.

Adverse effects of the virostatic drugs

- **Cidofovir**
 - **nephrotoxicity** – proteinuria, creatinine increase; acute and even with delay;
 - good hydration, together with probenecid
 - potentially to **chronic renal failure** with dialysis
 - other more common neutropenia, headache, nausea, vomiting, alopecia, rash, weakness and fever. Described also ocular toxicity.
- **Oseltamivir**
 - most frequent AE are nausea, vomiting and belly pain
- **Ribavirine**
 - **Haematopoietic disorders, depression, teratogenic effect (inhalation)** from that reason there must not be expomed men or women about the conception. In case of higher cumulative dose risk of teratogenicity lasts for months; nausea, pain in belly....




However – for success of the therapy is still crucial ...



... reconstitution of immunity!

Why we observe emerging viruses?

1. Climate changes



Why we observe emerging viruses?

1. Climate changes

Avance progresivo del dengue en América Latina

Década del 70, Década del 80, Década del 90 hasta 2008

- Bahian equine encephalitis virus, BEEV
- Eastem equine encephalitis virus, EEEV
- Missouri virus, MDV
- Norham virus, NDV
- Bebaru virus, BEBV
- Chikungunya virus, CHIKV
- Mayaro virus (-Una virus), MAYV-UNAV
- Oryongyong virus, ONNV
- Rosa River Virus, RRV
- Semli forest virus, SFV
- Venezuelan Equine Encephalitis virus, VEEV
- Cabesou virus, CABV
- Everglades virus, EVEV
- Mosao das Pedras virus, MDPV
- Mucambo virus, MUCV
- Rio Negro virus, RNV
- Western Equine Encephalitis Virus, WEEV
- Aura Virus, AURAV
- Sindbis Virus, SINV
- Babanki Virus, SINV-B
- Kyzylgach virus, SINV-K
- Odelbo Virus, SINV-O
- Whataroa virus, WHAV
- Highlands J virus, HJV
- Buggy Creek Virus, BCV
- Fort Morgan Virus, FMV
- Tonate virus, TONV

Why we observe emerging viruses?

2. Changes in human behaving and travelling

- E.g. expansion of Peoples Republic China activities in Africa
- Fly time
Amsterdam – Sydney shortest trip 27 hours and 20 minutes – less then 2 days...
-

Why we observe emerging viruses?

2. Changes in behaving of the people and travelling

Refugees crisis Epidemiological diseases

- Vaccination absence, or low frequency

Polio outbreak in the Middle East - update

Ongoing transmission in the Syrian Arab Republic with international spread

As of 20 March 2014, in the Syrian Arab Republic a total of 37 WPV1 cases have been reported: 25 cases by the Syrian Arab Republic Ministry of Health, and 12 cases from contested areas (Aleppo, Edlib and Deir Al Zour) not yet reflected in official figures. The most recent case had onset of paralysis on 17 December 2013, from Edlib.

World Health Organization

Why we observe emerging viruses?

3. More immunosuppression

- from 2008 WHO recognized 100 800 solid organ transplants in 104 countries per year (approx. 90% world population).
- 69 400 kidney (46% from living donors)
- 20 200 liver (14.6% from living donors)
- 5 400 heart
- 3 400 lungs
- 2400 pancreas

Approx. 110 000 HSCT per year.

- More monoclonal antibodies (anti-CD20, CD52, TNF- α ...) ...

Rovnováha u imunosuprimovaného pacienta

Steroids more then > 2 mg/kg – highly lymphotoxic (used e.g. in NHL, ALL...)

Why we observe emerging viruses?

4. Better detection (even in new) – treatment – resistance

Molecular-biological techniques

Direct and relative cheap detection based on NA

Reasonable time for detection of the agents

Relatively cheap detection of new viruses

CHIP technique was used in new WUV and KIV polyomavirus detection in 2007, which were detected in respiratory tract.

Why we observe emerging viruses?

4. Better detection – treatment – resistance

Why to act?

4. Better detection – treatment – resistance

Virostatic therapy


Nejčastěji používaná virostatika používaná při léčbě α -herpesviróvých infekcí (podle ECCL3):

- famciclovir
- acyclovir
- valacyclovir
- ledipasvir

and more

Guanine trifosfát (GTP)

Ležky první volby



BioSafety Level 4

Filoviridae

Mononegavirales: gene order

3' [Nucleo-protein] [Matrix protein] [Membrane protein(s)] [polymerase] 5'

- ss (-) RNA
- Helical nucleocapsid 13-20 nm wide
- Ebola virus and Marburg virus
- highly infectious 1-10 virions
- **High mortality**

Source: Brooks DJ, Carroll KC, Butler JS, Meyer SA, Moshiri TA, Jarrett M, et al. *Adaptation of the Filoviridae genome to the structure of the nucleocapsid.* *Journal of Virology* 74:1111-1118 (2000).

BioSafety Level 4

Filoviridae

Nature Reviews | Microbiology
<http://www.nature.com/nrmicro/journal/v13/n11/images/nrmicro3524-f1.jpg>

BioSafety Level 4

Filoviridae

Source: Centers for Disease Control and Prevention; World Health Organisation

BioSafety Level 4

Filoviridae

Ebola virus disease

Mortality rate 25-90%

Ebola, which first appeared in outbreaks in Sudan and DR Congo in 1976, is a severe and often fatal disease with no known specific treatment or vaccine. It has since killed more than 1,500 people in parts of Africa.

SOURCE
 In Africa, particular species of fruit bats are considered possible natural hosts for Ebola virus.

TRANSMISSION
 Infected bats are thought to transmit the disease to humans, or indirectly through other animals which are hunted for their meat.

DAMAGE
 Incubation period is from two to 21 days. Death from the disease is often caused by multiple organ failure and tissue death.

Targets in the body

- Hepatocytes, functional cells of the liver
- Endothelial cells, which form the linings of the blood vessels
- phagocytes, blood cells that absorb foreign particles


Symptoms

- Fever
- Sore throat
- Severe headache
- Muscle pain
- Intense weakness
- Vomiting
- Diarrhea
- Impaired liver and kidney function
- Internal and external bleeding

Note: List of animals is not exhaustive.
 Sources: Centers for Disease Control and Prevention; World Health Organisation
<http://doi.org/10.1038/nrmicro3524-f1>

BioSafety Level 4

Filoviridae



SYMPTOMS

- Early stages
- Advanced stages

Symptoms: Headache, Fever, Fatigue, Bleeding from eyes, nose and mouth, Muscle pain, Sore throat, Impaired liver and kidney, Diarrhoea, Vomiting, Rash, Internal and external bleeding

Preventative measures

- Stop contact with infected animals and the consumption of their meat
- Isolate the sick
- Prompt disposal of victims' bodies
- Disinfect homes of dead and infected
- Protective clothing for healthcare workers

Therapy: study only


ZMapp – 3 Ab

at the moment not available!!!!

Source: WHO

BioSafety Level 4

Filoviridae



Ebola outbreaks

2014 outbreak* of whom: died

Number of infections in each outbreak

Legend: 1976-2013, 2014 (current), Fruit bat habitat

Sources: WHO; IUCN

BioSafety Level 4


Filoviridae

2014 EBoV in West Africa (13th April 2016)

-Ebola outbreak: Total Cases: 28,652

Laboratory-Confirmed Cases: 15,261 Total deaths: 11,235



THE EBOLA EPIDEMIC



BioSafety Level 4

Filoviridae

- Double gloves
- Boot covers that are waterproof and go to at least mid-calf or leg covers
- Single use fluid resistant or impermeable gown that extends to at least mid-calf or coverall without intergraded hood.
- Respirators, including either N95 respirators or powered air purifying respirator (PAPR)
- Single-use, full-face shield that is disposable
- Surgical hoods to ensure complete coverage of the head and neck
- Apron that is waterproof and covers the torso to the level of the mid-calf should be used if Ebola patients have vomiting or diarrhoea

Viral exanthematic diseases

Childhood exanthema diseases

Classical name	„systematic exant. name“	Pathogen
Measles (rubeola)	1 st childhood disease	morbillivirus
Scarlet fever	2 nd childhood disease	Streptococcus pyogenes
Rubella (German measles)	3 rd childhood disease	Rubivirus
Filatov-Duke's disease (pseudoscarlantina)	4 th childhood disease	Coxsackie and Echoviruses
Erythema infectiosum	5 th childhood disease	Parvovirus B19
Exanthema subitum – Roseola infantum	6 th childhood disease	HHV-6 and HHV-7

Chicken pox - VZV